155 related articles for article (PubMed ID: 31104458)
1. A rare side effect: eltrombopag associated hyperpigmentation.
Atay H; Kelkitli E; Turgut M
G Ital Dermatol Venereol; 2020 Dec; 155(6):803-804. PubMed ID: 31104458
[No Abstract] [Full Text] [Related]
2. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
3. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
4. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
[No Abstract] [Full Text] [Related]
5. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
[No Abstract] [Full Text] [Related]
7. [Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
Cheng H; Wang X; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):612. PubMed ID: 32397030
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
Fang M; Song H; Zhang J; Li S; Shen D; Tang Y
Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag-cyclosporin A in treating severe aplastic anaemia.
Sathiamoorthy KS; Manikandan S
Lancet Haematol; 2024 Jun; 11(6):e397. PubMed ID: 38796186
[No Abstract] [Full Text] [Related]
13. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
[No Abstract] [Full Text] [Related]
14. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
15. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
McCormack PL
Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag-cyclosporin A in treating severe aplastic anaemia - Authors' reply.
Scheinberg P
Lancet Haematol; 2024 Jun; 11(6):e398. PubMed ID: 38796188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
